Identifying novel therapies for the treatment of CDK4/6 inhibitor-resistant patients is of great importance. Here, the authors demonstrate that PLK1 inhibition is a potential therapeutic target in CCND1-driven and in RB-positive Palbociclib-resistant breast cancers.
- Elodie Montaudon
- Joanna Nikitorowicz-Buniak
- Elisabetta Marangoni
